Dr. Gurtman is accepting the 2022 Health Industry Visionary Award on behalf of Pfizer, Inc.
Alejandra Gurtman, MD, is Vice President of Pfizer Vaccine Clinical Research and Development, and is currently the RSV (Respiratory Syncytial Virus) Clinical Franchise Lead responsible for leadership and oversight of the RSV adult and maternal immunization programs including licensure and post licensure requirements. Alejandra joined the Vaccine Research and Development group in 2005 and has over 30 years of clinical research experience. Over the last two years Dr. Gurtman was a critical member of the Pfizer’s COVID 19 vaccine program supporting all aspects of development and strategy. In particular, she was instrumental in bringing the adolescent and pediatric program forward for Emergency Use Authorization.
Before this role, Dr. Gurtman was the Global Clinical Lead for the Staphylococcus aureus vaccine (SA4Ag) and prior to that, she led the Prevnar 13 Pediatric Program through all phases of development. She also provided significant strategic and tactical support to the Prevnar 13 Adult Program and studies performed in high-risk immunocompromised children and adults.
Dr. Gurtman received her medical school and internal medicine training at the University of Buenos Aires, School of Medicine, Argentina, and postdoctoral training as fellow and chief fellow of infectious diseases at Mount Sinai School of Medicine, New York. She served on the faculty of the Mt. Sinai School of Medicine rising to Associate Professor. In her academic role she gained experience in conduct of clinical trials, care of high-risk populations, and was the founder and director for the travel medicine program.